Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Gastroenterology
Published in: BMC Gastroenterology 1/2010

Open Access 01-12-2010 | Review

Nutrigenomics Therapy of Hepatisis C Virus Induced-hepatosteatosis

Authors: Qing Liu, Stig Bengmark, Shen Qu

Published in: BMC Gastroenterology | Issue 1/2010

Login to get access

Abstract

Nutrigenomics is a relatively new branch of nutrition science, which aim is to study the impact of the foods we eat on the function of our genes. Hepatosteatosis is strongly associated with hepatitis C virus infection, which is known to increase the risk of the disease progression and reduce the likelihood of responding to anti- virus treatment. It is well documented that hepatitis C virus can directly alter host cell lipid metabolism through nuclear transcription factors. To date, only a limited number of studies have been on the effect of human foods on the nuclear transcription factors of hepatitis C virus -induced hepatosteatosis.
Three nutrients, selected among 46 different nutrients: β-carotene, vitamin D2, and linoleic acid were found in a cell culture system to inhibit hepatitis C virus RNA replication. In addition, polyunsaturated fatty acids (PUFAs) especially arachidonic acid (AA), docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA) have been demonstrated to inhibit hepatitis C virus RNA replication. These PUFAs, in particular the highly unsaturated n-3 fatty acids change the gene expression of PPARa and SREBP, suppress the expression of mRNAs encoding key metabolic enzymes and hereby suppress hepatic lipogenesis and triglyceride synthesis, as well as secretion and accumulation in tissues. A recent prospective clinical trial of 1,084 chronic hepatitis C patients compared to 2,326 healthy subjects suggests that chronic hepatitis C patients may benefit from strict dietary instructions.
Increasing evidence suggest that some crucial nuclear transcription factors related to hepatitis C virus -associated hepatosteatosis and hepatitis C virus RNA itself can be controlled by specific anti- hepatitis C virus nutrition. It seems important that these findings are taken into account and specific nutritional supplements developed to be used in combination with interferon as adjunctive therapy with the aim to improve both the early as well as the sustained virological response.
Literature
1.
Ferguson LR, Shelling AN, Lauren D: For Nutrigenomics New Zealand. Nutrigenomics and gut health: meeting report from an international conference in Auckland, New Zealand. Genes Nutr. 2007, 2: 157-60. 10.1007/s12263-007-0046-1.CrossRefPubMedPubMedCentral
2.
Ferguson LR, Peterman I, Hübner C, Philpott M, Shellin AN: Uncoupling gene-diet interactions in inflammatory bowel disease (IBD). Genes Nutr. 2007, 2: 71-3. 10.1007/s12263-007-0012-y.CrossRefPubMedPubMedCentral
3.
4.
Jonsson JR, Barrie HD, O'Rourke P, Clouston AD, Powell EE: Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. Hepatology. 2008, 48: 80-7. 10.1002/hep.22311.CrossRefPubMed
5.
Loguercio C, Federico A, Masarone M, Torella R, Blanco CD, Persico M: The Impact of Diet on Liver Fibrosis and on Response to Interferon Therapy in Patients with HCV-Related Chronic Hepatitis. Am J Gastroentero. 2008, 103: 3159-66. 10.1111/j.1572-0241.2008.02159.x.CrossRef
6.
Asselah T, Rubbia-Brandt L, Marcellin P, Negro F: Steatosis in chronic hepatitis C: why does it really matter?. Gut. 2006, 55: 123-130. 10.1136/gut.2005.069757.CrossRefPubMedPubMedCentral
7.
Seeff LB: Natural history of chronic hepatitis C. Hepatology. 2002, 36: S35-S46. 10.1002/hep.1840360706.CrossRefPubMed
8.
Bartenschlager R, Sparacio S: Hepatitis C virus molecular clones and their replication capacity in vivo and in cell culture. Virus Res. 2007, 127: 195-207. 10.1016/j.virusres.2007.02.022.CrossRefPubMed
9.
Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chrétien Y, Koike K, Pessayre D, Chapman J, Barba G, Bréchot C: Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J. 2002, 16: 185-94. 10.1096/fj.01-0396com.CrossRefPubMed
10.
Lettéron P, Sutton A, Mansouri A, Fromenty B, Pessayre D: Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology. 2003, 38: 133-40. 10.1053/jhep.2003.50309.CrossRefPubMed
11.
Enjoji M, Nakamuta M, Kinukawa N, Sugimoto R, Noguchi K, Tsuruta S, Iwao M, Kotoh K, Iwamoto H, Nawata H: Beta-lipoproteins influence the serum level of hepatitis C virus. Med Sci Monit. 2000, 6: 841-844.PubMed
12.
Petit JM, Benichou M, Duvillard L, Jooste V, Bour JB, Minello A, Verges B, Brun JM, Gambert P, Hillon P: HCV-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis and liver fibrosis. Am J Gastroenterol. 2003, l98: 1150-1154.
13.
Lerat H, Kammoun HL, Hainault I, Mérour E, Higgs MR, Callens C, Lemon SM, Foufelle F, Pawlotsky JM: Hepatitis C virus proteins induce lipogenesis and defective triglyceride secretion in transgenic mice. J Biol Chem. 2009, 284: 33466-74. 10.1074/jbc.M109.019810.CrossRefPubMedPubMedCentral
14.
Domitrovich AM, Felmlee DJ, Siddiqui A: Hepatitis C virus nonstructural proteins inhibit apolipoprotein B100 secretion. J Biol Chem. 2005, 280: 39802-8. 10.1074/jbc.M510391200.CrossRefPubMed
15.
Mirandola S, Realdon S, Iqbal J, Gerotto M, Dal Pero F, Bortoletto G, Marcolongo M, Vario A, Datz C, Hussain MM, Alberti A: Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology. 2006, 130: 1661-9. 10.1053/j.gastro.2006.02.035.CrossRefPubMed
16.
Shimano H: Sterol regulatory element-binding protein family as global regulators of lipid synthetic genes in energy metabolism. Vitam Horm. 2002, 65: 167-94. full_text.CrossRefPubMed
17.
Horton JD, Goldstein JL, Brown MS: SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002, 109: 1125-31.CrossRefPubMedPubMedCentral
18.
Shimano H: Sterol regulatory element-binding protein family as global regulators of lipid synthetic genes in energy metabolism. Vitam Horm. 2002, 65: 167-94. full_text.CrossRefPubMed
19.
Barrera G, Toaldo C, Pizzimenti S, Cerbone A, Pettazzoni P, Dianzani MU, Ferretti C: The Role of PPAR Ligands in Controlling Growth-Related Gene Expression and their Interaction with Lipoperoxidation Products. PPAR Res. 2008, 2008: 524671-CrossRefPubMedPubMedCentral
20.
21.
Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev. 1999, 20: 649-688. 10.1210/er.20.5.649.PubMed
22.
Cheng Y, Dharancy S, Malapel M, Desreumaux P: Hepatitis C virus infection down-regulates the expression of peroxisome proliferator-activated receptor alpha and carnitine palmitoyl acyl-CoA transferase 1A. World J Gastroenterol. 2005, 11: 7591-6.CrossRefPubMedPubMedCentral
23.
Jump DB, Botolin D, Wang Y, Xu J, Demeure O, Christian B: Docosahexaenoic acid (DHA) and hepatic gene transcription. Chem Phys Lipids. 2008, 153: 3-13. 10.1016/j.chemphyslip.2008.02.007.CrossRefPubMedPubMedCentral
24.
Castera L, Chouteau P, Hezode C: Hepatitis C Virus-Induced Hepatocellular Steatosis. Am J Gastroenterol. 2005, 100: 711-15. 10.1111/j.1572-0241.2005.40898.x.CrossRefPubMed
25.
Tanaka N, Moriya K, Kiyosawa K, Koike K, Gonzalez FJ, Aoyama T: PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest. 2008, 118: 683-94.PubMedPubMedCentral
26.
Waris G, Felmlee DJ, Negro F, Siddiqui A: Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. J Virol. 2007, 81: 8122-30. 10.1128/JVI.00125-07.CrossRefPubMedPubMedCentral
27.
Bernsmeier C, Duong FH, Christen V, Pugnale P, Negro F, Terracciano L, Heim MH: Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C. J Hepatol. 2008, 49: 429-40. 10.1016/j.jhep.2008.04.007.CrossRefPubMed
28.
Sheikh MY, Choi J, Qadri I, Friedman JE, Sanyal AJ: Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology. 2008, 47: 2127-33. 10.1002/hep.22269. Review.CrossRefPubMed
29.
Yano M, Ikeda M, Abe K, Dansako H, Ohkoshi S, Aoyagi Y, Kato N: Comprehensive Analysis of the Effects of Ordinary Nutrients on Hepatitis C Virus RNA Replication in Cell Culture. Antimicrob Agents Chemother. 2007, 51: 2016-27. 10.1128/AAC.01426-06.CrossRefPubMedPubMedCentral
30.
Appel N, Schaller T, Penin F, Bartenschlager R: From structure to function: new insights into hepatitis C virus RNA replication. J Biol Chem. 2006, 281: 9833-9836. 10.1074/jbc.R500026200.CrossRefPubMed
31.
Fillebeen C, Rivas-Estilla AM, Bisaillon M, Ponka P, Muckenthaler M, Hentze MW, Koromilas AE, Pantopoulos K: Iron inactivates the RNA polymerase NS5B and suppresses subgenomic replication of hepatitis C virus. J Biol Chem. 2005, 280: 9049-57. 10.1074/jbc.M412687200.CrossRefPubMed
32.
Fried MW: Side effects of therapy of hepatitis C and their management. Hepatology. 2002, 36: S237-44. 10.1002/hep.1840360730.CrossRefPubMed
33.
Ikeda M, Abe K, Dansako H, Nakamura T, Naka K, Kato N: Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system. Biochem Biophys Res Commun. 2005, 329: 1350-9. 10.1016/j.bbrc.2005.02.138.CrossRefPubMed
34.
Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N: Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology. 2006, 44: 117-25. 10.1002/hep.21232.CrossRefPubMed
35.
Ikeda M, Yi M, Li K, Lemon SM: Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. J Virol. 2002, 76: 2997-3006. 10.1128/JVI.76.6.2997-3006.2002.CrossRefPubMedPubMedCentral
36.
Kapadia SB, Chisari FV: Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci USA. 2005, 102: 2561-6. 10.1073/pnas.0409834102.CrossRefPubMedPubMedCentral
37.
Sealls W, Gonzalez M, Brosnan MJ, Black PN, DiRusso CC: Dietary polyunsaturated fatty acids (C18: 2 omega6 and C18: 3 omega3) do not suppress hepatic lipogenesis. Biochim Biophys Acta. 2008, 1781: 406-14.CrossRefPubMed
38.
Leclercq S, Skrzypski J, Courvoisier A, Gondcaille C, Bonnetain F, André A, Chardigny JM, Bellenger S, Bellenger J, Narce M, Savary S: Effect of dietary polyunsaturated fatty acids on the expression of peroxisomal ABC transporters. Biochimie. 2008, 90: 1602-7. 10.1016/j.biochi.2008.05.022.CrossRefPubMed
39.
Kim HJ, Lee KT, Park YB, Jeon SM, Choi MS: Dietary docosahexaenoic acid-rich diacylglycerols ameliorate hepatic steatosis and alter hepatic gene expressions in C57BL/6J-Lep(ob/ob) mice. Mol Nutr Food Res. 2008, 52: 965-73. 10.1002/mnfr.200700315.CrossRefPubMed
40.
Nakamura MT, Nara TY: Gene regulation of mammalian desaturases. Biochem Soc Trans. 2002, 30: 1076-9. 10.1042/BST0301076. Review.CrossRefPubMed
41.
Ren B, Thelen AP, Peters JM, Gonzalez FJ, Jump DB: Polyunsaturated fatty acid suppression of hepatic fatty acid synthase and S14 gene expression does not require peroxisome proliferator-activated receptor alpha. J Biol Chem. 1997, 272: 26827-32. 10.1074/jbc.272.43.26827.CrossRefPubMed
42.
Dallongeville J, Baugé E, Tailleux A, Peters JM, Gonzalez FJ, Fruchart JC, Staels B: Peroxisome proliferator-activated receptor alpha is not rate-limiting for the lipoprotein-lowering action of fish oil. J Biol Chem. 2001, 276: 4634-9. 10.1074/jbc.M008809200.CrossRefPubMed
43.
Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev. 1999, 20: 649-88. 10.1210/er.20.5.649.PubMed
44.
Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW: Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes. 2001, 50: 411-7. 10.2337/diabetes.50.2.411.CrossRefPubMed
45.
Guerre-Millo M, Gervois P, Raspé E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B: Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000, 275: 16638-42. 10.1074/jbc.275.22.16638.CrossRefPubMed
46.
Jump DB: The biochemistry of n-3 polyunsaturated fatty acids. J Biol Chem. 2002, 277: 8755-8. 10.1074/jbc.R100062200.CrossRefPubMed
47.
Deckelbaum RJ, Worgall TS, Seo T: n-3 fatty acids and gene expression. Am J Clin Nutr. 2006, 83: 1520-1525.
48.
Johnson RA, Hamilton JA, Worgall TS, Deckelbaum RJ: Free fatty acids modulate intermembrane trafficking of cholesterol by increasing lipid mobilities: novel 13C NMR analyses of free cholesterol partitioning. Biochemistry. 2003, 42: 1637-45. 10.1021/bi0264465.CrossRefPubMed
49.
Worgall TS, Johnson RA, Seo T, Gierens H, Deckelbaum RJ: Unsaturated fatty acid-mediated decreases in sterol regulatory element-mediated gene transcription are linked to cellular sphingolipid metabolism. J Biol Chem. 2002, 277: 3878-85. 10.1074/jbc.M102393200.CrossRefPubMed
50.
Rosenwald AG, Machamer CE, Pagano RE: Effects of a sphingolipid synthesis inhibitor on membrane transport through the secretory pathway. Biochemistry. 1992, 31: 3581-90. 10.1021/bi00129a005.CrossRefPubMed
51.
Yao ZM, Vance DE: The active synthesis of phosphatidylcholine is required for very low density lipoprotein secretion from rat hepatocytes. J Biol Chem. 1988, 263: 2998-3004.PubMed
52.
Lee GS, Yan JS, Ng RK, Kakar S, Maher JJ: Polyunsaturated fat in the methionine-choline-deficient diet influences hepatic inflammation but not hepatocellular injury. J Lipid Res. 2007, 48: 1885-96. 10.1194/jlr.M700181-JLR200.CrossRefPubMed
53.
Rinella ME, Green RM: The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol. 2004, 40: 47-51. 10.1016/j.jhep.2003.09.020.CrossRefPubMed
54.
Peter JR, Moffat JN, Brian RW: A Choline-Deficient Diet Exacerbates Fatty Liver but Attenuates Insulin Resistance and Glucose Intolerance in Mice Fed a High-Fat Diet. Diabetes. 2006, 55: 2015-2020. 10.2337/db06-0097.CrossRef
55.
Dela Peña A, Leclercq I, Field J, George J, Jones B, Farrell G: NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology. 2005, 129: 1663-74. 10.1053/j.gastro.2005.09.004.CrossRefPubMed
56.
Larter CZ, Yeh MM, Cheng J, Williams J, Brown S, dela Pena A, Bell-Anderson KS, Farrell GC: Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation. J Gastroenterol Hepatol. 2008, 23: 267-75. 10.1111/j.1440-1746.2007.05157.x.CrossRefPubMed
57.
Hussein O, Grosovski M, Lasri E, Svalb S, Ravid U, Assy N: Monounsaturated fat decreases hepatic lipid content in non-alcoholic fatty liver disease in rats. World J Gastroenterol. 2007, 13: 361-8.CrossRefPubMedPubMedCentral
Metadata
Title
Nutrigenomics Therapy of Hepatisis C Virus Induced-hepatosteatosis
Authors
Qing Liu
Stig Bengmark
Shen Qu
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2010
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/1471-230X-10-49

Other articles of this Issue 1/2010

BMC Gastroenterology 1/2010 Go to the issue

Research article

Small intestinal mucosa expression of putative chaperone fls485

Research article

The gene-reduction effect of chromosomal losses detected in gastric cancers

Research article

Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease

Research article

Polymorphisms of genes coding for ghrelin and its receptor in relation to colorectal cancer risk: a two-step gene-wide case-control study

Research article

Effective in vivo and ex vivogene transfer to intestinal mucosa by VSV-G-pseudotyped lentiviral vectors

Research article

Efficacy of capillary pattern type IIIA/IIIB by magnifying narrow band imaging for estimating depth of invasion of early colorectal neoplasms
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits